Alimera Sciences, Inc. (ALIM) |
3.59 0.05 (1.41%) 04-23 16:00 |
Open: | 3.5732 |
High: | 3.63 |
Low: | 3.5199 |
Volume: | 16,155 |
Market Cap: | 188(M) |
PE Ratio: | -4.27 |
Exchange: | NASDAQ Global Market |
Industry: | Drug Manufacturers - Specialty & Generic |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 4.24 |
Resistance 1: | 3.87 |
Pivot price: | 3.67 |
Support 1: | 3.26 |
Support 2: | 2.71 |
52w High: | 4.38 |
52w Low: | 1.56 |
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
EPS | -0.840 |
Book Value | 0.880 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | -24.93 |
Operating Margin (%) | 2.75 |
Return on Assets (ttm) | -1.2 |
Return on Equity (ttm) | -158.8 |
Fri, 19 Apr 2024
Analysts Expect Alimera Sciences, Inc. (NASDAQ:ALIM) To Breakeven Soon - Simply Wall St
Sat, 13 Apr 2024
Alimera Sciences, Inc. (NASDAQ:ALIM) Sees Large Growth in Short Interest - MarketBeat
Thu, 07 Mar 2024
Alimera Sciences: Q4 Earnings Snapshot - Quartz
Thu, 07 Mar 2024
Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript - Seeking Alpha
Thu, 07 Mar 2024
Alimera Sciences Inc (ALIM) Reports Significant Revenue Growth in Q4 and Full Year 2023 - Yahoo Finance
Wed, 06 Mar 2024
Alimera Sciences, Inc. (NASDAQ:ALIM) Has Found A Path To Profitability - Yahoo Finance
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |